CXCL8 and pachyonychia congenita: Ongoing studies are exploring the potential of IL-6 blockade as a treatment for combating PC’s inflammatory and oncogenic effects [16,17] and may hold implications for IL-8 inhibition or synergistic benefit in combination blockade.